- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Discusses SGLT2 Inhibitor Uptake Among Cardiologists, Nephrologists
As time goes on, we're finding out more and more benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors, said Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association.
Transcript
In the past decade, we’ve seen the SGLT2 class burst on to the scene, first in type 2 diabetes, and now in heart failure and renal disease. Are you seeing more patients with type 2 diabetes being prescribed these therapies by a cardiologist or nephrologist?
SGLT2 medications have really been a game changer in the world of diabetes, and we're finding out more and more benefits. As you know, this started off as a story about cardiovascular disease, it's now extended to renal disease. One initiative that the American Diabetes Association is leading in collaboration with the American Heart Association, is a program called No Diabetes by Heart. That effort, that has been a 3-year activity by us, aimed at consumers in general, at people with diabetes and at providers and health systems, has been moving the needle. We've done some recent survey data across the country that indicates that, particularly to the target providers that we've been looking at, and that is cardiologists and nephrologists, are more confident and more knowledgeable about these medications, and now increasingly view this as their responsibility to prescribe these medications. So we are seeing progress, but we still have further to go.
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
